|1.||Colao, Annamaria: 26 articles (03/2015 - 06/2002)|
|2.||Pivonello, Rosario: 16 articles (03/2015 - 06/2002)|
|3.||Lombardi, Gaetano: 16 articles (10/2008 - 06/2002)|
|4.||Colao, A: 10 articles (03/2015 - 01/2000)|
|5.||Molitch, Mark E: 10 articles (12/2014 - 10/2002)|
|6.||Vilar, Lucio: 7 articles (01/2015 - 07/2007)|
|7.||Di Sarno, Antonella: 7 articles (01/2013 - 02/2003)|
|8.||Lombardi, G: 7 articles (08/2008 - 01/2000)|
|9.||Guerra, Ermelinda: 6 articles (01/2013 - 01/2005)|
|10.||Saveanu, Alexandru: 6 articles (05/2012 - 01/2006)|
01/01/2015 - "Our findings suggest that, cabergoline can be used as a first-line therapy in giant prolactinomas because tumoral shrinkage without a surgical procedure and rapid improvement in visual field defect is achieved with this medical treatment."
01/01/2015 - "Rapid improvement in visual loss with cabergoline treatment in a giant prolactinoma case: 5 years survey."
04/01/2010 - "Efficacy of cabergoline on rapid escalation of dose in men with macroprolactinomas."
04/01/2004 - "These data demonstrate that cabergoline treatment is as effective and safe in men as in women with prolactinoma and can be successfully used as primary therapy even in men bearing large macroprolactinomas."
04/01/1997 - "Although the present data were not obtained in a formal study we conclude that cabergoline is an effective and well-tolerated treatment for macroprolactinoma patients."
01/01/2008 - "Cabergoline normalized serum PRL level, shrank the tumor mass remarkably, and caused marked improvement of visual acuity. "
11/01/2012 - "Rapid improvement in visual field with cabergoline in suprasellar tumor in a young adult: Clinical dilemma solved and surgery averted."
06/01/1996 - "During two further years of follow up, the improvement in PRL levels, gonadal function, and tumor size has persisted during cabergoline administration, and three patients have experienced a further decline in PRL and/or tumor size. "
02/01/2015 - "Some studies have shown that a significant and rapid tumor shrinkage resulting from treatment with cabergoline can occur and it is thought that some complications are related with this tumor regression, as in the presented case."
07/01/1999 - "The aim of this study was to examine, in a very large number of hyperprolactinemic patients, the ability to normalize PRL levels with cabergoline, to determine the effective dose and tolerance, and to assess the effect on clinical symptoms, tumor shrinkage, and visual field abnormalities. "
|3.||Parkinson Disease (Parkinson's Disease)
06/01/1996 - "The 13 patients randomized to cabergoline and completing the study had significantly improved Unified Parkinson's Disease Rating Scale (UPDRS) motor scores and timed hand-tapping test scores. "
11/01/1996 - "Our results indicate that the long-lasting effects of cabergoline could be beneficial for treating Parkinson's disease."
03/01/1993 - "Unified Parkinson's Disease Rating Scale scores, Hoehn and Yahr stage of disease, and computerized measures of motor performance improved significantly with cabergoline treatment. "
09/13/2002 - "While cabergoline is commonly used to treat the motor dysfunction of Parkinson's disease, it may also be effective in inhibiting oxidative stress, a possible mechanism of dopaminergic neuronal degeneration in Parkinson's disease."
01/01/2001 - "Efficacy of cabergoline in long-term use: results of three observational studies in 1,500 patients with Parkinson's disease."
01/01/2005 - "In conclusion, the excellent therapeutic efficacy and the lack of adverse events with Cabergoline promotes its use as a first line therapy of hyperprolactinemia due to pituitary microadenoma."
03/01/1997 - "Cabergoline (CAB), a new, potent, and long-lasting PRL-lowering agent, was shown to be effective in tumoral hyperprolactinemia. "
06/01/1989 - "We conclude that cabergoline is effective treatment for hyperprolactinemia. "
09/01/2007 - "Predictors of remission of hyperprolactinaemia after long-term withdrawal of cabergoline therapy."
12/01/2013 - "Studies had to have assessed the prevalence, odds, or risk of cardiac valve regurgitation in patients who underwent chronic treatment with cabergoline for PD or hyperprolactinemia compared with patients with the same diseases whose therapy did not include cabergoline or another ergot-DA. "
05/01/2011 - "Cabergoline is widely considered to be poorly effective in acromegaly. "
01/01/2008 - "Remission of acromegaly following long-term therapy with cabergoline: report of two cases."
05/01/2011 - "We systematically reviewed all trials of cabergoline therapy for acromegaly published up to 2009 in four databases (PubMed, Pascal, Embase, and Google Scholar). "
01/01/2004 - "Fourteen other patients with more typical, active postoperative acromegaly were administered cabergoline in a 6-month, open label, dose-escalation study. "
02/01/1998 - "Cabergoline in the treatment of acromegaly: a study in 64 patients."
|2.||Dopamine Agonists (Dopamine Agonist)
|4.||Levodopa (L Dopa)
|7.||Insulin-Like Growth Factor I (IGF-1)
|8.||Gonadotropin-Releasing Hormone (GnRH)
|9.||Risperidone (Risperdal Consta)
|2.||Activities of Daily Living (ADL)